From being a founding member of the UCB Rare Disease Organization in 2019, to her work on the launch of a targeted therapy in generalized myasthenia gravis for a subpopulation without an approved treatment, Dana Fallaize has consistently demonstrated she is an exemplary leader and a strategic thinker. Those skills sit atop a wealth of experience. The roles that Fallaize has held include global commercial operations and launch readiness lead, rare disease global marketing lead and, currently, head of commercialization and analytics.
At UCB, she has been a pioneer on a number of fronts, including navigating compressed timelines in response to FDA priority review. Her ability to quickly assess a situation, determine the best path forward and motivate her team was especially evident with the Rystiggo launch in July 2023.
Fallaize also values her time with her family, traveling, skiing and cheering from the sidelines for her daughters.
